Literature DB >> 21515380

Strategy for improvement of enteropeptidase efficiency in tag removal processes.

Marine E Gasparian1, Maxim L Bychkov, Dmitry A Dolgikh, Mikhail P Kirpichnikov.   

Abstract

Enteropeptidase (synonym: enterokinase, EC 3.4.21.9) is a heterodimeric serine protease of the intestinal brush border that activates trypsinogen by highly specific cleavage of the trypsinogen activation peptide following the sequence (Asp)(4)-Lys. It has also great biotechnological interest because of the unique substrate specificity of the serine protease domain. The high degree of specificity exhibited by enteropeptidase makes it a suitable reagent for cleaving recombinant proteins to remove affinity or other tags. However often unwanted cleavages elsewhere in the protein occurred during cleavage of fusions when high amount of enzyme is required. In this study we have improved the efficiency of fusion proteins cleavage by enteropeptidase by substitution of the Lys residue by Arg in specific cleavage sequence (Asp)(4)-Lys. We have demonstrated that 3-6-fold lower amounts of the catalytic subunit of human and bovine enteropeptidase is required for 95% cleavage of Trx/TRAIL and Trx/FGF-2 fusions with (Asp)(4)-Arg cleavage sequence in comparison to native sequence (Asp)(4)-Lys. As a result, reduced amount of non-specifically cleaved peptide fragments were observed during cleavage of (Asp)(4)-Lys/Arg mutated fusions. These findings overcome limitations of enteropeptidase in tag removal processes during recombinant proteins purification and extend its commercial benefit in the biopharmaceutical industry.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515380     DOI: 10.1016/j.pep.2011.04.005

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  8 in total

1.  Human enteropeptidase light chain: bioengineering of recombinants and kinetic investigations of structure and function.

Authors:  Eliot T Smith; David A Johnson
Journal:  Protein Sci       Date:  2013-03-26       Impact factor: 6.725

2.  New strategy for high-level expression and purification of biologically active monomeric TGF-β1/C77S in Escherichia coli.

Authors:  Yana V Kim; Marine E Gasparian; Eduard V Bocharov; Rita V Chertkova; Elena N Tkach; Dmitry A Dolgikh; Mikhail P Kirpichnikov
Journal:  Mol Biotechnol       Date:  2015-02       Impact factor: 2.695

3.  Production of Recombinant Active Human TGFβ1 in Nicotiana benthamiana.

Authors:  Aditya Prakash Soni; Juhee Lee; Kunyoo Shin; Hisashi Koiwa; Inhwan Hwang
Journal:  Front Plant Sci       Date:  2022-05-31       Impact factor: 6.627

4.  Essential calcium-binding cluster of Leptospira LipL32 protein for inflammatory responses through the Toll-like receptor 2 pathway.

Authors:  Yueh-Yu Lo; Shen-Hsing Hsu; Yi-Ching Ko; Cheng-Chieh Hung; Ming-Yang Chang; Hsiang-Hao Hsu; Ming-Jeng Pan; Yen-Wei Chen; Ching-Hung Lee; Fan-Gang Tseng; Yuh-Ju Sun; Chih-Wei Yang; Rong-Long Pan
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

Review 5.  An overview of enzymatic reagents for the removal of affinity tags.

Authors:  David S Waugh
Journal:  Protein Expr Purif       Date:  2011-08-19       Impact factor: 1.650

6.  Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.

Authors:  Maxim L Bychkov; Marine E Gasparian; Dmitry A Dolgikh; Mikhail P Kirpichnikov
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

7.  Active Components of Leptospira Outer Membrane Protein LipL32 to Toll-Like Receptor 2.

Authors:  Shen-Hsing Hsu; Cheng-Chieh Hung; Ming-Yang Chang; Yi-Ching Ko; Huang-Yu Yang; Hsiang-Hao Hsu; Ya-Chung Tian; Li-Fang Chou; Rong-Long Pan; Fan-Gang Tseng; Chih-Wei Yang
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Tuning Scorpion Toxin Selectivity: Switching From KV1.1 to KV1.3.

Authors:  Andrei M Gigolaev; Alexey I Kuzmenkov; Steve Peigneur; Valentin M Tabakmakher; Ernesto L Pinheiro-Junior; Anton O Chugunov; Roman G Efremov; Jan Tytgat; Alexander A Vassilevski
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.